nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.02.2008

New oral Xa and IIa inhibitors: updates on clinical trial results

verfasst von: Sylvia Haas

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Heparins and VKAs have been the cornerstones of anticoagulation therapy for several decades and these agents have become most important drugs in the primary and secondary prevention of venous and arterial thromboembolic disease. Although effective, their use has been hampered by numerous limitations. In the search for new agents matching the ‘ideal’ anticoagulant profile, a number of different steps in the coagulation cascade have been targeted, including direct thrombin inhibition, and direct inhibition of Factor Xa. There are currently a host of promising new agents at various stages of development and clinical evaluation. With potential benefits including predictable efficacy, rapid onset of action, ability to bind clot-bound coagulation factors and no requirement for therapeutic monitoring, these new agents are set to improve the management of thromboembolic disorders.

Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):338S–400SPubMedCrossRef

Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):401S–428SPubMedCrossRef

Ansell J, Hirsh J, Dalen J et al (2001) Managing oral anticoagulant therapy. Chest 119(1 Suppl):22S–38SPubMedCrossRef

Hart RG, Benavente O, McBride R et al (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131(7):492–501PubMed

Haas S (2003) Medical indications and considerations for future clinical decision making. Thromb Res 109(Suppl 1):S31–S37PubMedCrossRef

Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):188S–203SPubMedCrossRef

Weitz JI, Hudoba M, Massel D et al (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86(2):385–391PubMedCrossRef

Di Nisio M, Middeldorp S, Buller HR (2005) Direct thrombin inhibitors. N Engl J Med 353(10):1028–1040PubMedCrossRef

Stangier J, Rathgen K, Stahle H et al (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292–303PubMedCrossRef

10.

Wienen W, Stassen JM, Priepke H et al (2007) Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost 5(6):1237–1242PubMedCrossRef

11.

Eriksson BI, Dahl OE, Buller HR et al (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3(1):103–111PubMedCrossRef

12.

Eriksson BI, Dahl OE, van Dijk CN et al (2006) A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery (The RE-MODEL Trial). Blood 108:Abstr. 573

13.

Wallentin LC, Ezekowith M, Simmers TA et al (2005) Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation—a dose finding trial with comparison to warfarin. Eur Soc Cardiol Cong (abstr):P2949

14.

Bauer KA (2006) New anticoagulants. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology, pp 450–456

15.

Alexander JH, Yang H, Becker RC et al (2005) First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost 3(3):439–447PubMedCrossRef

16.

Paccaly A, Frick A, Rohatagi S et al (2006) Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol 46(1):37–44PubMedCrossRef

17.

Paccaly A, Ozoux ML, Chu V et al (2005) Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost 94(6):1156–1163PubMed

18.

Hinder M, Paccaly A, Frick A et al (2005) Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers. Thromb Haemost 93(4):794–795PubMed

19.

Hinder M, Frick A, Rosenburg R et al (2006) Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid. Thromb Haemost 95(2):224–228PubMed

20.

Perzborn E, Strassburger J, Wilmen A et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(3):514–521PubMedCrossRef

21.

Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873–880PubMedCrossRef

22.

Kubitza D, Haas S (2006) Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 15(8):843–855PubMedCrossRef

23.

Eriksson BI, Borris L, Dahl OE et al (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4(1):121–128PubMedCrossRef

24.

Turpie AG, Fisher WD, Bauer KA et al (2005) BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3(11):2479–2486PubMedCrossRef

25.

Eriksson BI, Borris LC, Dahl OE et al (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114(22):2374–2381PubMedCrossRef

26.

Fisher WD, Eriksson BI, Bauer KA et al (2007) Rivaroxaban for thromboprophylaxis after orthopedic surgery: pooled analysis of two studies. Thromb Haemost 97(6):931–937PubMed

27.

Weitz JI (2006) Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 96(3):274–284PubMed

28.

Lassen MR, Davidson BL, Gallus A et al (2006) A phase II randomized, double-blind, eight-arm, parallel-group, dose–response study of Apixaban, a new oral factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery—on behalf of the Apixaban Investigators. Blood 108:Abst. 574

29.

Agnelli G, Haas S, Ginsberg JS et al (2007) A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 5(4):746–753PubMedCrossRef

30.

Eriksson BI, Turpie AG, Lassen MR et al (2005) YM150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. Blood 106:Abstr. 1865

31.

Morishima Y, Furugohri T, Isobe K et al (2004) In vitro characteristics, anticoagulant effects and in vivo antithrombotic efficacy of a novel, potent and orally active direct factor Xa inhibitor, DU-176b. Blood 104(11):Abstr. 1862

32.

Zafar MU, Gaztanga J, Velez M et al (2006) A phase-I study to assess the antithrombotic properties of Du-176b: an orally active direct factor-Xa inhibitor. J Am Coll Cardiol 47:Abstr. 288A

Titel: New oral Xa and IIa inhibitors: updates on clinical trial results
verfasst von: Sylvia Haas
Publikationsdatum: 01.02.2008
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 1/2008
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-007-0108-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

New oral Xa and IIa inhibitors: updates on clinical trial results

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Common clinical variables predict warfarin maintenance dose and therapeutic resistance

Effect of low-dose vitamin K supplementation in patients on warfarin with fluctuating international normalized ratios

Azathioprine induced warfarin resistance: case reports and potential interaction mechanism

An analysis of anticoagulant adverse drug events in a large community teaching hospital

Clinical challenges of management of a coumarin rodenticide (brodifacoum) toxicity vs. warfarin toxicity: case report

Impact of a pharmacist-managed inpatient anticoagulation service for warfarin titration with follow-on care at outpatient anticoagulation clinic

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin